Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu

References

• Bousquet PJ, Demoly P, Devillier P, et al. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol. 2013;160(4):393–400.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006;117(1):158–162.
   PubMed Web of Science ®Google Scholar
• Van Cauwenberge P, Van Hoecke H, Kardos P, et al. The current burden of allergic rhinitis amongst primary care practitioners and its impact on patient management. Prim Care Respir J. 2009;18(1):27–33.
   PubMedGoogle Scholar
• De La Hoz Caballer B, Rodríguez M, Fraj J, et al. Allergic rhinitis and its impact on work productivity in primary care practice and a comparison with other common diseases: the Cross-sectional study to evAluate work Productivity in allergic Rhinitis compared with other common dIseases (CAPRI) study. Am J Rhinol Allergy. 2012;26(5):390–394.
   PubMed Web of Science ®Google Scholar
• Bodtger U, Linneberg A. Remission of allergic rhinitis: An 8-year observational study. J Allergy Clin Immunol. 2004;114(6):1384–1388.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Incorvaia C, Scurati S, et al. Patient-related factors in rhinitis and asthma: the satisfaction with allergy treatment survey. Curr Med Res Opin. 2011;27(5):1005–1011.
   PubMed Web of Science ®Google Scholar
• Demoly P, Chiriac AM, Berge B, et al. Reasons for prescribing second generation antihistamines to treat allergic rhinitis in real-life conditions and patient response. Allergy Asthma Clin Immunol. 2014;10(1):29.
   PubMed Web of Science ®Google Scholar
• Mullol J, Bartra J, Del Cuvillo A, et al. Specialist-based treatment reduces the severity of allergic rhinitis. Clin Exp Allergy. 2013;43(7):723–729.
   PubMed Web of Science ®Google Scholar
• Meltzer E, Ratner P, Bachert C, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161(4):369–377.
   PubMed Web of Science ®Google Scholar
• Price D, Scadding G, Ryan D, et al. The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy. 2015;5:39.
   PubMed Web of Science ®Google Scholar
• Pitman R, P. N, Parker C, et al. Episode pattern and healthcare utilisation in patients with seasonal allergic rhinitis. Allergy. 2012;67:A885.
   Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160.
   PubMed Web of Science ®Google Scholar
• Price D, Smith P, Hellings P, et al. Current controversies and challenges in allergic rhinitis management. In: Expert Rev Clin Immunol. 2015. p. 1–13.
   Google Scholar
• Costa DJ, Amouyal M, Lambert P, et al. How representative are clinical study patients with allergic rhinitis in primary care? J Allergy Clin Immunol. 2011;127(4):920–6 e1.
   PubMed Web of Science ®Google Scholar
• Price D, Bateman ED, Chisholm A, et al. Complementing the randomized controlled trial evidence base. Evolution not revolution. Ann Am Thorac Soc. 2014;11(Suppl 2):S92–8.
   PubMedGoogle Scholar
• Konstantinou GN. Pragmatic trials: how to adjust for the ‘Hawthorne effect’? Thorax. 2012;67(6): 562. author reply 562
   PubMed Web of Science ®Google Scholar
• Adham TM. Treatment of allergic rhinitis with desloratadine: results of a multinational observational study in the middle East gulf region. World Allergy Organ J. 2011;4(8):130–134.
   PubMedGoogle Scholar
• Bousquet J, Bodez T, Gehano P, et al. Implementation of guidelines for allergic rhinitis in specialist practices. A randomized pragmatic controlled trial. Int Arch Allergy Immunol. 2009;150(1):75–82.
   PubMed Web of Science ®Google Scholar
• Price D, Kemp L, Sims E, et al. Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. Prim Care Respir J. 2010;19(3):266–273.
   PubMedGoogle Scholar
• Ratner PH, Meltzer EO, Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2009;73(5):651–657.
   PubMed Web of Science ®Google Scholar
• Berger WE, Kaiser H, Gawchik SM, et al. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. Otolaryngol Head Neck Surg. 2003;129(1):16–23.
   PubMed Web of Science ®Google Scholar
• Mintz M, Garcia J, Diener P, et al. Triamcinolone acetonide aqueous nasal spray improves nocturnal rhinitis-related quality of life in patients treated in a primary care setting: the Quality of Sleep in Allergic Rhinitis study. Ann Allergy Asthma Immunol. 2004;92(2):255–261.
   PubMed Web of Science ®Google Scholar
• Marogna M, Bruno M, Massolo A, et al. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: A long-term (13-year) retrospective study in real life. Int Arch Allergy Immunol. 2007;142(1):70–78.
   PubMed Web of Science ®Google Scholar
• Zeldin Y, Weiler Z, Magen E, et al. Safety and efficacy of allergen immunotherapy in the treatment of allergic rhinitis and asthma in real life. Isr Med Assoc J. 2008;10(12):869–872.
   PubMed Web of Science ®Google Scholar
• Santilli J, Nathan R, Glassheim J, et al. Patients receiving immunotherapy report it is effective as assessed by the rhinitis outcomes questionnaire (ROQ) in a private practice setting. Ann Allergy Asthma Immunol. 2001;86(2):219–221.
   PubMed Web of Science ®Google Scholar
• Seidenberg J, Pajno GB, Bauer CP, et al. Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents. J Investig Allergol Clin Immunol. 2009;19(2):125–131.
   PubMed Web of Science ®Google Scholar
• Roger A, Justicia J-L, Navarro LÁ, et al. Observational study of the safety of an ultra-rush sublingual immunotherapy regimen to treat rhinitis due to house dust mites. Int Arch Allergy Immunol. 2011;154(1):69–75.
   PubMed Web of Science ®Google Scholar
• Milani M, Pecora S, Burastero S, et al. Observational study of sublingual specific immunotherapy in persistent and intermittent allergic rhinitis: the EFESO trial. Curr Med Res Opin. 2008;24(9):2719–2724.
   PubMed Web of Science ®Google Scholar
• Acquistapace F, Agostinis F, Castella V, et al. Efficacy of sublingual specific immunotherapy in intermittent and persistent allergic rhinitis in children: an observational case-control study on 171 patients. The EFESO-children multicenter trial. Pediatr Allergy Immunol. 2009;20(7):660–664.
   PubMed Web of Science ®Google Scholar
• Pastorello EA, Losappio L, Milani S, et al. 5-grass pollen tablets achieve disease control in patients with seasonal allergic rhinitis unresponsive to drugs: a real-life study. J Asthma Allergy. 2013;6:127–133.
   PubMedGoogle Scholar
• Irani C, Saleh RA, Jammal M, et al. High-dose sublingual immunotherapy in patients with uncontrolled allergic rhinitis sensitized to pollen: a real-life clinical study. Int Forum Allergy Rhinol. 2014;4(10):802–807.
   PubMed Web of Science ®Google Scholar
• De Castro G, Zicari AM, Indinnimeo L, et al. Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children’s real life. Eur Rev Med Pharmacol Sci. 2013;17(16):2225–2231.
   PubMed Web of Science ®Google Scholar
• Marogna M, Spadolini I, Massolo A. Rhinitis and asthma co-morbidity in respiratory allergy due to house dust mite: results of an observational open controlled parallel group study in real-life setting. Eur Ann Allergy Clin Immunol. 2005;37(4):135–142.
   PubMedGoogle Scholar
• Olivieri M, Mohaddes Zadeh MR, Talamini G, et al. Local nasal immunotherapy and bronchial hyperreactivity in seasonal allergic rhinitis: an observational pilot study. J Investig Allergol Clin Immunol. 2000;10(5):300–304.
   PubMed Web of Science ®Google Scholar
• Ogino S, Nagakura T, Okubo K, et al. Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated. Int Arch Allergy Immunol. 2009;149(3):239–245.
   PubMed Web of Science ®Google Scholar
• Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23(7):495–503.
   PubMed Web of Science ®Google Scholar
• Klimek L, Bachert C, Mosges R, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015;36(1):40–47.
   PubMed Web of Science ®Google Scholar
• Wessel F, Chartier A, Meunier J-P, et al. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons - the GRAAL trial. Clin Drug Investig. 2012;32(7):451–463.
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–476.
   PubMed Web of Science ®Google Scholar
• Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg. 2015;152(2):197–206.
   PubMed Web of Science ®Google Scholar
• Mösges R. All of ARIA in one puff? Int Arch Allergy Immunol. 2014;163(3):163–164.
   PubMed Web of Science ®Google Scholar
• Ellis AK, Zhu Y, Steacy LM, et al. A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Allergy Asthma Clin Immunol. 2013;9(1):16.
   PubMed Web of Science ®Google Scholar
• Derendorf H, Munzel U, Petzold U, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol. 2012;74(1):125–133.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bachert C, Bernstein J, et al. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. Expert Opin Pharmacother. 2015;16(6):913–928.
   PubMed Web of Science ®Google Scholar
• Dymista Summary of Product Characteristics [Internet]. Bishop’s Stortford: Meda Pharmaceuticals. 2016 [ cited 2016 Jan 19]. Available from: https://www.medicines.org.uk/emc/medicine/27579
   Google Scholar
• Dymista HIGHLIGHTS OF PRESCRIBING INFORMATION.
   Google Scholar
• Hampel FC, Ratner PH, Van Bavel J, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010;105(2):168–173.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, LaForce C, Ratner P, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012;33(4):324–332.
   PubMed Web of Science ®Google Scholar
• Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282–1289 e10.
   PubMed Web of Science ®Google Scholar
• Berger WE, Shah S, Lieberman P, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract. 2014;2(2):179–185.
   PubMed Web of Science ®Google Scholar
• Stjarne P, S V, Theman K, et al. Real-life effectiveness of a new allergic rhinitis (MP29-02) in Sweden. Presented at European Academy of Allergy and Clinical Immunology Congress; 2015 Jun 6–10; Barcelona, Spain.
   Google Scholar
• Dollner R, L.L. P, Sheyauldeen S, et al. Real-life effectiveness of a new allergic rhinitis therapy (MP29-02) in Norway. Presented at European Academy of Allergy and Clinical Immunology Congress; 2015 Jun 6–10; Barcelona, Spain.
   Google Scholar
• Haahr P, J. C, Blegvad S, et al. Real life effectiveness of a new allergic rhinitis therapy (MP29-02) in Denmark. Presented at Euroeapn of Allergy and Clinical Immunology Congress; 2015 Jun 6–10; Barcelona, Spain.
   Google Scholar
• Hellings P, M. A, Fokkens W, et al. A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clin Transl Allergy. 2015;5:36.
   PubMedGoogle Scholar
• Bousquet PJ, Combescure C, Neukirch F, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007;62(4):367–372.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bachert C, Canonica GW, et al. Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy. 2009;64(10):1516–1523.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bachert C, Canonica GW, et al. Efficacy of desloratadine in persistent allergic rhinitis - a GA(2)LEN study. Int Arch Allergy Immunol. 2010;153(4):395–402.
   PubMed Web of Science ®Google Scholar
• Demoly P, Bousquet PJ, Mesbah K, et al. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. Clin Exp Allergy. 2013;43(8):881–888.
   PubMed Web of Science ®Google Scholar